Skip to main content
Cardiff Oncology, Inc. logo

Cardiff Oncology, Inc. — Investor Relations & Filings

Ticker · CRDF ISIN · US14147L1089 LEI · 549300AHOLZBHHYFWP04 US Professional, scientific and technical activities
Filings indexed 1,012 across all filing types
Latest filing 2024-08-08 Earnings Release
Country US United States of America
Listing US CRDF

About Cardiff Oncology, Inc.

https://cardiffoncology.com/

Cardiff Oncology, Inc. is a clinical-stage biotechnology company developing novel cancer therapies. The company's primary focus is on leveraging the inhibition of Polo-like kinase 1 (PLK1), a well-validated oncology drug target. Its lead drug candidate, onvansertib, is an oral PLK1 inhibitor being evaluated in clinical trials. These programs test onvansertib in combination with standard-of-care therapeutics for various cancer indications. The company's strategy is designed to target tumor vulnerabilities to overcome treatment resistance and improve clinical outcomes for patients with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Cardiff Oncology, Inc. It specifically mentions Item 2.02 "Results of Operations and Financial Conditions" and states that the company issued a press release announcing financial results for the second quarter ended June 30, 2024. The document itself does not contain detailed financial statements or substantive financial data but rather furnishes the press release as an exhibit. The length of the document is 2874 characters, which is relatively short and consistent with an announcement rather than a full financial report. According to the rules, such a document that announces or furnishes a press release with financial results but does not contain the full financial data should be classified as an Earnings Release (ER).
2024-08-08 English
10-Q
Interim / Quarterly Report Q2 2024
2024-08-08 English
FORM 4
Director's Dealing
2024-07-01 English
FORM 4
Director's Dealing
2024-07-01 English
FORM 4
Director's Dealing
2024-07-01 English
FORM 4
Director's Dealing
2024-07-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.